AUTHOR INDEX

Aleman, C. 634
Ankel, Helmut 517
Arai, T. 693
Armstrong, J.A. 571
Attallah, A. 289
Augenstein, D.C. 169

Baer, G.M. 526
Baglioni, C. 471
Ball, L.A. 487
Baron, Samuel 1, 150, 344, 395, 672
Bekesi, J.G. 614
Berg, K. 225
Billardon, C. 427
Billelo, J.A. 604
Billiau, A. 184, 427
Blalock, J. Edwin 344, 350
Bocci, V. 336
Borden, Ernest, C. 122
Borecký, L. 575
Brodsky, I. 663
Broeze, R. 443
Brown, R.E. 479
Burke, D.C. 13, 64

Cantell, K. 427
Carter, W.A. 37, 663
Cayley, P.J. 479
Cesario, T.C. 359
Chandrabose, Kuttikkatt A. 499
Chany, C. 307
Chany-Fournier, F. 307
Chiang, T.-R. 198
Chirigos, Michael A. 611
Cioe, L. 381
Cornbleet, M.A. 144
Costello, L. 198
Cruttenden, V.C. 169
Cuatrecasas, Pedro 499
Currie, G.A. 144

Dahl, H. 370
Dalton, B.J. 23
De Clercq, E. 76
de Ferra, F. 471
De Ley, M. 184
De Maeyer, E. 420
De Maeyer-Guignard, J. 420
De Somer, P. 184
Degre, M. 388
Dewdney, J.M. 144
Dianzani, Ferdinando 1, 99
Djeu, Julie Y. 591
Dolei, A. 381
Dougherty, J.P. 443
Durrer, B. 43

Edwards, C.R. 169
Edy, V.G. 169
Epstein, C.J. 324
Epstein, L.B. 324
Esber, E. 289
Evinger, M. 31

Falcoff, E. 427
Familletti, P.C. 31
Fantes, K.H. 240
Fauconnier, B. 522
Finter, N.B. 19, 175
Fleischmann, W.R. Jr. 298, 317
Floyd-Smith, G. 443
Frezzotti, R. 555
Fridman, W. 427
Friedman, M. 452
Friedman, R.M. 313

Galasso, George J. 294, 543
Galin, M.A. 555
Georgiades, J.A. 179, 260
Gera, A. 213
Gifford, George E. 59
Gilbert, C.S. 479
Gillespie, D.H. 37, 663
Glasgow, Lowell A. 532
Goeddel, David V. 192
Greenberg, S.B. 549
Greene, J.J. 663
Gresser, Ion 582
Grossberg, Sidney E. 158, 274, 294, 332
Guarari-Rotman, D. 559
Guerra, R. 555
Gutterman, J. 626

Harmon, M.W. 549
Harned, Cindy L. 363
Havell, Edward A. 280
Herberman, Ronald 591
Heron, I. 225
Hilario, R. 634
Hill, J.M. 634
Hill, N.O. 634
Hirsch, M.S. 566
Ho, Monto 129
Hobbs, D.S. 43, 250

Hooks, J.J. 164
Hopps, H. 289
Howie, V. 150
Huang, Kun-Yen 375

Imanishi, J. 647
Inglot, Anna D. 402
Inoue, E. 287

Jameson, P. 135
Jayaram, B.M. 443
Johnson, Howard M. 344, 411
Johnston, M.D. 19

Kahn, A. 634
Kawade, Yoshima 219
Kelder, B. 31
Kern, Earl R. 532
Kerr, I.M. 479
Kimchi, A. 452
Kirchner, H. 89
Kishida, T. 647
Knight, E. Jr. 209
Knight, M. 479
Kohase, M. 693
Kohno, S. 693
Krammer, P.H. 89
Krim, Mathilde 681
Krishnamurti, Chitra 517
Kumar, Surendra 395
Kung, H.-F. 43

Lackovič, V. 575
Ladizensky, E. 559
Landolfo, S. 89
Langford, M.P. 84, 150, 538
Lapidot, Y. 452
Lefkowitz, E.J. 317
Lengyel, P. 443
Levine, Arthur S. 653
Levy, Hilton B. 653
Levy, W.P. 43, 198, 250
Loebenstein, G. 213
Lubiniecki, A.S. 169
Lucero, M.A. 427

MacDonald, E.M. 150
MacDonald, Hector S. 517
Maeda, S. 31, 198
Magdelenat, H. 427
Marcucci, F. 89
Marcus, Philip I. 70
Maroney, P.A. 471
McCandliss, R. 198
Merlin, G. 452
Miggiano, V. 43
Monahan, T. 99
Moutsopolos, H.M. 164
Moschera, J.A. 43, 250
Myers, M. 543

Nagai, M. 693
Nerland, Donald E. 363
Neta, Ruth 435
Niethammer, D. 641
Nilsen, T.M. 471
Notkins, A.L. 164

Ogburn, C.A. 23
Ohtsuki, Kenzo 493
Ortaldo, John R. 591

Panet, A. 452
Pang, R.H.L. 108
Papermaster, Vera M. 672
Pardue, A. 634
Perussia, B. 597
Peschle, C. 381
Pestka, Sidney 31, 43, 198, 250, 591
Petricciani, J. 289
Pitha, P.M. 604
Planterose, D.N. 144
Pottathil, Raveendran 499
Pouillart, P. 427

Quesada, J. 626

Rapaport, S. 452
Rehberg, E. 31, 198
Reitmeyer, E.J. 150
Revel, M. 452, 559
Reynolds, Craig W. 591
Riggin, C.H. 604
Roboz, J.P. 614
Rollag, H. 388
Romano, A. 559
Rossi, G.B. 381
Rousset, S. 307
Rovenský, J. 575
Rozengurt, E. 509
Rubinstein, M. 250
Ruddle, F.H. 94

Sabran, Jan L. 332
Salvin, S.B. 435
Samanta, H. 443
Samuel, Charles E. 463
Santiano, M. 99

Schmidt, J. 43
Schwarz, L.A. 298
Scott, G.M. 549
Secher, D. 225
Sedmak, J.J. 274
Silverman, R.H. 479
Simon, M.M. 89
Slate, D. 94
Smith, Eric M. 350
Sonnenfeld, Gerald 363
Spackman, D.A. 144
Spitalny, George L. 280
Staehelin, T. 43
Stähli, C. 43
Stanton, G. John 1, 84, 150, 344, 538, 591
Stein, S. 250
Stewart, W.E. II 271
Stocker, J. 43
Stone-Wolff, D.S. **108**
Strander, H. 621
Strayer, D.R. 663
Stringfellow, Dale A. 116
Sulkowski, E. 234
Takacs, B. 43
Tan, Y.H. 94, 287
Taylor, J.L. 158
Taylor-Papidimitrou, J. 509
Tilles, J.G. 359
Timenon, Tuomo 591
Torrence, P.F. 76
Treuner, J. 641
Trinchieri, G. 597
T'so, P.O.P. 663
Tyrrell, D.A.J. 549

Van Damme, J. 184
Vilček, J. 108

Weigent, Douglas A. 84, 150
West, D.K. 487
Wolf, D. 452
Wreschner, D.H. 479

Yelverton, Elizabeth 192
Yip, Y.K. 108

Zawatsky, R. 89

SUBJECT INDEX

accelerated storage tests 274
acridanones 158
acridines 129
ACTH 346-358, 402
actin fibers 314
actinomycin D 101, 171, 345, 371-372, 493
acute hemorrhagic conjunctivitis 538
acute otitis media 151
adenine arabinoside, synergism with alpha interferon 363
adenovirus(es) 538, 559
bilateral infection 562, 565
sensitivity to interferon 560
type 8 559
adenylate cyclase, membrane associated 116, 120
adjuvant, antitumor action 655
adrenocorticotropic hormone. See ACTH
adriamycin 360
aerosol interferon 551
affinity chromatography. See chromatography
aggregation of interferon 307
albumin 676, 680
alcoholism 140
alkaline phosphatase 666, 669
alkyl diamines 159
allantoic fluid 397
allgeneic cells 85
alloantigens 89, 91
allograft survival 421
alpha interferon(s) 13-14, 19, 23-27, 37, 43, 50, 84-86, 99, 192, 199-200, 299, 307
bacterially synthesized 192, 241
chemical properties 241
cloned 271, 630
genes 46, 192-193, 200, 205, 271
herpes therapy 571-572
heterogeneity of 176, 192, 240, 241
hybrid properties 413-414
iodinated 211
modification of 272
molecular weight 240, 259
purification 225
stability 544
subtypes 23-24, 26, 32, 44, 192-195, 252, 259, 543, 595
alpha/beta adrenergic receptors 351
amanitine 101
amino acid analysis 252
amino acid sequence(s) 14, 26, 47, 193, 207-208, 220-221, 241, 250, 252, 258, 280
aminomethyltrioxsalen 472
amino sugar analysis 252
amphotericin B 123
amplification. See potentiation
animal interferon, in vivo systems 139. See also: baboon; murine
anthraquinones 129, 159
antibacterial activities 388, 391
antibody, antibodies. See also: assay; monoclonal
affinity 31
anti-theta 89
binding 44-45
dependent cytolytic cells (K cells) 596, 598
HbsAg 649
heterologous 24ff
to interferon 262, 522, 658
monoclonal 15-16
to murine interferon 219-220, 284
neutralizing, clinical presence 629
neutralizing, beta interferon 287, 642
to rabies virus 526
reference antisera 296
response, regulation of 411, 413
anticellular effect of interferon 298, 300, 324, 339, 370, 611, 642, 653
inhibition of 319
antigenic
composition of interferon 15
crossreactivity 26, 283
heterogeneity 25
homology 220
properties of interferon 23ff
anti-inflammatory drugs, nonsteroidal 502
antimalarial activity of interferon 389
antimitogenic effect 325, 452
antineoplastic agents 653
antiproliferative effect 32, 325, 405
antitumor
action, animal systems 610, 613

antitumor (continued)
activity, double-stranded RNA 146
activity, poly ICLC 659
effect of interferon 298, 300, 408, 427, 509, 512, 582ff, 592, 621, 626, 653
potentiation 305-306
therapy, dosage 643
trials 649
antiviral
action of interferon 31-32, 325, 406, 428, 463, 693
activity of modified alpha interferon 272
agents 214
drugs 158
drugs and human ocular diseases 555
drugs, resistance to 566
effect, effect of gangliosides on 308
effect, molecular mechanism 603
effect, reversal of 510
mechanisms 471
state, inhibition of 383-384
state, potentiated 298, 303-304
arborviruses 136
assay(s) 19, 48-49, 145, 295, 364
calibration of 295-296, 684
chromatographic 20
enzyme immunoassay 46, 48
macrophage precursor cell 147
radioimmune 20, 46, 50, 56-59, 287, 480
red cell lysis 147
solid phase antibody binding 43, 54
synergistic, interferon-antibody 539
astatalon 363
autoantibody production 166
autoimmunity 164-166
avian infectious bronchitis virus (IBV) 139
avian reovirus 66

B cell tumors 626-627
B lymphocytes 85-86
baboon interferon 145-146
BALB/c mice 327
bacteria
gram-negative 389
gram-positive 389
bacterial
diseases 388
expressions of human interferons 198
infection, action of interferon 150ff
lipopolysaccharide 376, 378
bacterially processed alpha interferon 192, 241
beta-galactosidase 100
beta interferon 13-14, 19, 23-27, 31, 33, 37, 46, 94, 150, 299, 307, 314
brain tumor, therapy 693
chemical properties 242
herpes therapy 572
molecular weight 243
production, microcarrier 169ff
purification 234
radio labelled 210
sarcoma therapy 641
subtypes 95, 184-186, 242, 288
synthesis 202
tissue binding 544
β_2-microglobulin 427-430
binding of interferon to cells 38
binding of interferon target cells 517
bioassay. See assay
biphasic effects 382, 384
bladder tumor, treatment of 651
blood-brain barrier 693
blue tongue virus (BTV) 139-140
body fluids 359
bovine cells 19, 32
brain tumor, treatment of 650, 693
breast cancer 511-512, 611, 613, 626, 656
bromodeoxyuridine 176
buffy coats 14
Bureau of Biologics 289
butyrate 66

$CaCl_2$ 275
C57BL/6 cell, mouse 327
calcium and interferon production 122-123
cAMP 298, 344
campotothecin 378
cancer(s). See also leukemia; therapy; tumors
bladder 651
brain 650
breast 511-512, 611, 613, 626, 656

cancer(s) (continued)
cervical 573
embryonal 476
glioblastoma 695-696
laryngeal 546, 582, 628, 643, 657, 659
lung 650, 657
lymphoma 626-627, 656, 659
medulloblastoma 694, 696
melanoma 656
mesothelioma 657
osteosarcoma 622, 655
papilloma 546, 582, 623, 628, 643, 657, 659
prostatic 628, 665
squamous cell 636, 650
carbohydrate content
alpha interferon 240
beta interferon 242
murine interferon 243-244
carbohydrate moieties and species specifity 39
carcinoembryonic antigen (CEA) 427-429
catabolis 336-337
cell(s). See also L cells; natural killer cells; specific cell types
activation 517
B 92
bovine 19, 32
cycle 509
free translation systems 67
FS-4 641
GM 2504 145
growth, inhibition of 32, 654
growth, retardation 611
hybrid 67, 308
membrane glycoprotein 99, 314. See also membrane
modulators 452
multiplication inhibitory action 31
murine C243 219
murine, Ehrlich ascites tumor 219
murine, L. See L cells
P815y 600
proliferation, inhibition of 437
protective activity 397
surface receptor 325
V 3 145
cellular
differentiation 332, 666, 670
immunity, mediators of 611
ceramide 308, 518
cerebrospinal fluid, interferon levels 140
cervical carcinoma 573
chalones 408
chaotropic salts 236
chemotherapy, combined 535
chalones 408
chaotropic salts 236
chemotherapeutic agents 359, 559-560
chemotherapy, combined 535
chlamydia 388
cholera toxin 314, 384, 511
effect on antiviral activity 372
cholesterol esters 500-501
chorionic gonadotrophin 350
chromatographic assay 20
chromatography
adsorption 185, 236, 371, 673
affinity 226-227, 318
antibody affinity 24, 46, 54, 138, 280, 287, 352, 684
blue-sepharose 253, 258
controlled pore glass 236, 673, 675, 677
dye 237-238
gas-liquid 500, 506
gel filtration 121, 185, 241, 275-276, 278, 673, 679
high-performance liquid (HPLC) 31-32, 199, 250-251, 257, 259, 275
hydrophobic 181, 234-235
ion exchange 381
lectin affinity 234
metal chelate affinity 235
phenyl boronate affinity 235
reverse-phase 251
silicic acid 673, 675, 678, 680
chromosomal
assignments 66, 94
gene copies 193
segregation 94
chromosome(s)
2 14, 94
5 14, 94
9 14, 94
16, mouse 326
16, role in superinduction 95
21, 94, 324
cibacron blue F3GA 237-238
circulating immune complexes 166
circulating interferon 136ff, 164
circulating interferon, in double-stranded RNA therapy 664-666
clearance of interferon 336-337
clearance, mucociliary 551

clinical
application 48, 551, 642
research, constraints on 289
studies 543
trials 626, 647, 655
trials, cytomegalovirus 567-568
trials, leukocyte interferon 634
trials, production of interferon for 674
clone screening
hybridization 206-207
cloned
complementary DNA 193
interferon 271, 276, 630
interferons, activity of 26
clones 345. See also DNA
colchicine 309, 510
collagen formation 333
colloidal carbon 377
colon cancer 627
colony, hybridization 198
colostrum, antiviral activity of 396
combination therapy 643-644, 651
concanavalin A (Con A) 59, 90, 100, 110, 184, 234, 241, 314, 318, 320
sepharose 234
condylomata 546
conformation of polynucleotides 663ff
conjunctivitis, viral 647
contaminants of interferon preparations 289
controlled pore glass (CPG) desorption of gamma interferons 672-673. See also chromatography
cordycepin 102
corticosteroids 346, 559
corticotropin. See ACTH
Corynebacterium parvum 60, 376, 576, 591, 593
coxsackievirus A24 538
creatinine 666
creatine kinase, and differentiation 334
cross-reactivity 26, 37-38
C-type viruses 135ff
cyclic AMP 352, 403
of induced cell 116, 120
cyclic GMP, intracellular levels of 520
cyclic nucleotides, potentiation by 298
cyclohexamide 101, 171, 493
cycloxygenase activity and interferon resistence 502
cytochalasin B 309
cytochrome P-450 system, effect of interferon inducers on 363
cytokines 60-61
cytomegalic inclusion disease (CID) 566-567
cytomegalovirus 532, 566, 569
excretion 568
infection and hyporeactivity 133
murine 566
sensitivity in vitro 566
cytoplasmic lipid droplets 332
cytoskeletal filaments 333
cytostatic effect 339. See also anticellular effect
cytotoxic lymphocytes 61, 598
cytotoxicity 346, 658
antibody-dependent cell-mediated 596
lymphocyte-mediated 596
cytotoxin 437

Datura stramonium 214
Daudi cells 371
DEAE dextran 14, 122-123. See also inducers
delayed hypersensitivity 59, 421
denaturation human gamma interferon 673-674
desialylation 337
dexamethasone 353
differentiation
adipocyte, interferon inhibition 332
of cells 14
erythroid 454
muscle 333
diffusion of interferon 338
dimethylsulfoxide 138, 381, 383
diphenylhydantoin 365
diptheria toxoid 59
dissociation constant 517
diterpene esters 108
DNA
complementary (cDNA) 192ff, 241, 456
double-stranded 165
plasmid 198, 205
polymerase 649
proviral 606
recombinant 290

DNA (continued)
double-stranded
sequence 199-200, 202
DNA viruses 475
dosage, therapeutic, in eye infections 556
dose. See also therapy
cytomegalic inclusion disease 567
double-stranded RNA 663
intramuscular injection 544
malignancy, clinical trials 634ff
minimal 561
poly ICLC, maximum tolerable 659
requirements 549ff
route of application 646
tumor therapy 647, 649
double-stranded RNA. See RNA
Down syndrome 37-38, 324, 326, 421
drug metabolism 363

Ehrlich ascites tumor cells 444
eIF-2. See initiation factor eIF-2
eIF-2 alpha P phosphatase 466
electrophoresis 45, 228-229, 371
SDS 280
embryonal carcinoma 476
encephalitis 141, 649
encephalomyocarditis virus, replicative complexes 472
endonuclease 464
activation of 603
cleavage specificity 446
latent 445-446
endoribonuclease 471
endorphins 350, 352-353, 630
endotoxin 60, 291, 576. See also specific toxins
enhancement, rare earth salts 275
enterotoxin 389. See also toxin
enterovirus 70
enzyme immunoassays 46
enzymes, interferon-induced 443-444, 452
epitopes of human leukocyte interferon 45
Epstein-Barr virus 176, 642
erythropoietic differentiation 381ff
estradiol 360
ethidium bromide 475
ethylene glycol 275, 672-673, 675, 677
eukaryotic cell physiology, alterations 332
evolution 37
expression of interferon in microorganisms 192, 198
eye infections, human 140, 555, 559. See also keratoconjunctivitis

fatty acid cyclooxygenase 326
fatty acids 500-501, 506, 508
Fcγ-receptors 423
FDA requirements 289
fever, and interferon treatment 651. See also side effects
fibroblast(s) 23, 325, 509
fibroblast interferon. See beta interferon
fibronectin 314
5-azacytidine 665
5-bromodeoxyuridine 66
5-fluorouracil 360
5-6-dicholor-1-ribofuranosylbenzimidazole (DRB) 101
flourenones 129, 159
follicle stimulating hormone 352
Food and Drug Administration 289
freeze-fracture electron microscopy 313
Friend erythroleukemic cells 381
FS-4 cells 170

galactose oxidase 110
galactose residues, lymphocyte membrane bound 99
gamma interferon(s) 13-14, 23-27, 59, 84-86, 90-91, 99ff, 108, 298-299, 317, 326, 453ff
chemical properties 243
denaturation 673-674
induction 99, 160, 179, 184
molecular weight 243
production 179, 184, 261-262, 673ff
RNA, messenger 111
stability 276, 672
ganglioside, binding activity 38, 308
gangliosides 308, 384, 518
gap junctions 344
gene(s) 683
activation and interferon induction 122
alpha interferon 46, 192-193, 200, 205, 271
beta interferon 202
cluster 193
dosage 328
expression in E. coli 194

gene(s) (continued)
expression in yeast 194
interferon, in constitutive state 95
transcriptional control 95-96
genetic
control 324
regulation 94-95
variants. See subtypes
glioblastoma 695-696
glomerulonephritis, murine 523
glucosamine 221
glycolipoproteins 261-262
glycoprotein(s) 14, 221
hormones 308
membrane 99, 314
virion 605
glycosidase(s) 221, 337, 353
glycosylation 252
alpha interferon 240-241
effect of 25
inhibitors of 221
GM 2504 cells, interferon assay 145
GOT, serum 649
GPT, serum 649
graft versus host reaction 137
granulopoiesis 666, 670
growth factors 402ff, 510-511
growth inhibition 371, 509ff
guanidine thiocyanate 276

HeLa cells 371, 444, 481
HeLa cells, reovirus infected 473
heme regulatory inhibitor 495
hemin deficiency 465
hemoglobin synthesis, effect of interferon 381-382
hempoietic colony formation 48
hepatitis 140
B, chronic 363
chronic, B virus 546
viral, treatment of 649
virus, murine (MHV) 136
hepatocytes 337
herpes
labialis 140
keratitis 546
simplex virus 136, 532, 538, 555, 571, 648
therapy 571-572
zoster 545, 648
herpetic epithelial keratitis 556, 560
heterogeneity 15, 38, 281. See also subtypes
heterogeneity (continued)
alpha interferon 240-241
beta interferon 242, 288
catabolic 336
gamma interferon 260ff
inducer specific 138
murine interferon 243
heterologous cells 19, 281
heterologous cells, activity of interferon on 37-38
hexose monophosphate shunt 412
histamines 576, 585
histocompatibility antigens 314
homogeneous interferon, activity of 31
homologous antibodies 644
hormonal action of interferon 350ff, 402ff
hormone responses 346
hormones 344
host
defense factor 390
defenses 540
range 185-186
H-2 antigens 422
hybrid cell(s)
monkey/mouse 308
mouse/human 67
hybrid interferons 203
hybridomas 43ff
hydrocortisone 360
hydrophobicity, interferon 238, 244
hypergammaglobulinemia 166
hyporeactivity, mediators of 132
hyporeactivity, to systemic induction 129, 131
hyporesponsiveness 137, 659, 685

immune interferon. See gamma interferon
immune
complexes, circulating 166
modulation 31, 160, 366, 420, 611, 654
modulation, disease of 165, 168
reaction 60
response 339, 347
immunity, cell mediated 420, 654
immunoassay, human leukocyte interferon 48
immunoenhancement 422, 539
immunoglobin. See antibody
immunoregulation 89, 164, 319, 411, 455, 593. See also: immune modulation; immunosuppression

immunosuppression 61, 319, 347-348, 423, 566, 571, 616-617
impurities 289
inactivation of interferon 15, 550
inactivators 360
inducer(s) See also induction; mitogens; Newcastle disease virus; poly(I)·poly(C); prostaglandins; staphylococcal enterotoxin A
antigens 84
and anti-interferon serum 523
DEAE dextran 14, 122-123
effect of 25
of gamma interferon 160
interferon, cell membrane penetration 123
interferon, mechanism of activity 160
interferon, murine leukemia, treatment with 614
interferon, and rabies 526
mitogens, T cell 84
polyanionic 575
polynucleotide, hydrolysis of 130
receptor, interferon 78
of Type I interferon (alpha/beta) 158-160
uptake by target cells 116, 120
induction 13-14, 70-74, 76, 84, 90, 109, 122, 129ff, 144, 281, 427. See also inducer(s)
alpha interferon and ACTH 353
animal models 137-140
bacteria 150
calcium requirement 101
cell modulation 122
chemical, of interferon 158
defective interfering particles 72
double-stranded RNA 70-71, 663-664
enzyme 444
galactose oxidase 100
gamma interferon 99, 179, 184
herpes simplex virus 91
hyporesponsiveness 116
lipopolysaccharide, bacterial 131
lymphokines 160
messenger RNA 446
murine 135, 243-244
NK cells 160, 592-593
oxidative activation 100
priming 67, 125
proteins 446
protozoa 150
relationship between interferon and 2-5 oligo A system 79-80, 455
induction (continued)
sensitized lymphocytes 84
superinduction. See superinduction
synergistic action of TPA and PHA 110
systemic 129, 131
therapy 129
(2'-5') oligo A synthetase 455
viral 64, 73, 85, 135ff, 150, 219, 324
viral, in disease 166
in vivo 135ff
infections, viral, and hyporeactivity 133
infectious bovine rhinotracheitis 139
infectious bursal disease virus 139
influenza
B type 549
virus, heat inactivated 64
virus, treatment of 648
virus, type A 137-138
inhibition
of cellular differentiation 332
by diethyldithiocarbamate 502-503
of interferon 317-322
of tumor cell multiplication 503
inhibitors
of virus replication (IVR) 213ff
of virus replication, molecular weight of 216
ribosome associated, protein synthesis 464
initiation complexes 476
initiation factor eIF2 463-464, 466, 493
interactive effects of interferon mixtures 195. See also potentiation
intercellular communication 344
interferon alpha. See alpha interferon
interferon beta. See beta interferon
interferon gamma. See gamma interferon
interleukin 1 61, 108, 111, 436
interleukin 2 61, 111, 415, 436
intracellular multiplication of non-viral agents 390
ion transport 314
irradiation 611
irreversible denaturation, gamma interferon 674
isocytosine, structural requirements for induction by 129
isoelectric focusing, of gamma interferon 261-262

Japanese encephalitis virus 158
juvenile laryngeal papilloma 628-629, 643

juvenile laryngeal papillomatosis 657, 659

Karnofsky's criteria 651, 694
keratinocytes, human 510
keratitis 562
keratoconjunctivitis 556, 559, 647, 652
killer cell. See natural killer cell
Kimchi's kinase 495
kinase, histone H_1 494. See also protein kinase

laryngeal papilloma 582
laryngeal papilloma, juvenie 546
L-cells 64, 125, 219, 281, 313-314, 317, 326, 332, 345, 370, 479, 653
lectin(s) 234, 309, 353, 519. See also chromatography
  hepatic 337
leukapheresis 251
leukemia 613, 656, 659, 665
  alpha interferon therapy 635, 639
  cells, L1210 654
  chronic myelogenous 251
  murine 614-617
  murine, monocyte M1 334
  virus, Maloney 315
  viruses, IDU induced 604
leukocyte(s) 14
  activating factor 61. See also interleukin 1
  cultures, mixed 597
leukocyte interferon. See alpha interferon
levamisole 160
lipid metabolism 499
lipopolysaccharide 60, 363
lipoprotein 243
lipoproteins, viral inhibitors 396
local lesion response 214
localization of viruses 213
lung cancer 650, 657
lutenizing hormone 352
lymphoblastoid
  cells 32
  Daudi cell line 32-33
lymphocyte(s) 346, 596
  activation 59
  cytotoxicity of 420
  cytotoxicity, enhancement of 413
  helper 60
  splenic 314, 317
  subsets of T 90
lymphocyte(s) (continued)
  transfer system 346
lymphocytic choriomeningitis (LCM) virus 135
lymphokines 59, 166, 346, 409, 435
lymphoma 626-627
lymphoma, non-Hodgkins 656, 659
lymphoproliferation 89
lymphotoxin 437
lymphotoxicity 27
lyophilization of interferons 274
lysosomes 337
Lyt or Qat 5 surface markers 91

macrolide polyene antibiotics 123-124
macrophage(s) 281,375, 420
  activated 152, 376, 390, 611
  activating factor 435, 439
  effect of interferon on 439
  Ia-negative immature 92
  migration inhibitory factor 27, 60, 435, 438
major histocompatibility complex 421, 430
malarial organisms 151
Maloney leukemia virus 611
mammary carcinoma 511-512, 611, 613, 626, 656
medulloblastoma 694, 696
melanogenesis 346
melanoma, malignant 656
  treatment with double-stranded RNA 146
membrane, lymphocyte 99
membrane receptors, chemical composition 500, 526
mengovirus 299, 317, 320, 363
mengovirus, induction by 73
meningitis 141
mental retardation 140
mercatoethanol 15
mesothelioma 657
messenger RNA. See RNA
metabolism, drug 363
methotrexate 360
methylation 471, 487
mezerein 109
microcarrier, production of beta interferon 169ff
micrometasteses 655
migration, inhibitory factor 27, 60, 435, 438
milk, antiviral activity of 396

mitogen(s) 90, 509ff See also induction; inducers
induced interferon 59, 219, 317
T-cell 26, 89
mitogenic factor 435. See also interleukin 2
mixed lymphocyte culture(s) 59, 244, 436, 597
murine 91
MLC. See mixed lymphocyte culture(s)
MO57/2, mouse cell line 14
molecular
mechanisms of interferon action 463
weight 15, 240, 243, 259, 261
alpha interferon 240
beta interferon 243
gamma interferon 243
mouse interferon 15
Moloney murine sarcoma virus (MSV) 136-137
monoclonal antibody (antibodies) 15-16, 20, 23-24, 43-44, 95
column 46-47. See also chromatography
OKT3 reactive with human T cells 110
monocyte(s) 60, 85, 421
monokines 59
mononucleosis, infectious, heterophile-negative 566
mucopolysaccharide, antiviral activity of 397
multiple myeloma 626-627, 657, 659, 665
multiplication of virus, inhibition 395
multiplicity of infection 14
murine
antibodies to interferon 219-220, 284
beta interferon, heterogeneity of 222
cytomegalovirus 136
Ehrlich ascites tumor 219
fibroblasts 3T3 509
histocompatibility antigens 91
interferon molecular weight 15
interferons, alpha/beta 24
interferons, antigenic properties 280
L-cell interferon, radio labelled 210
L cells. See L cells
murine (continued)
leukemia viruses (MuLV) 135
lymphocyte cultures 89
prophylactic therapy 615
mycobacterium BCG 137
Mycobacterium bovis 59-60, 364, 389, 437
mycophage 137
mycoplasma 85, 388
myeloma 623
myelosuppression 627
myocardial cells 347
myxovirus, heat and UV inactivated 65

Namalwa cells 66, 109, 175
nasal washings 139
nasopharyngeal carcinoma 642, 657
natural defense of the body 399
natural killer (NK) cell(s) 61, 422, 576, 584, 590, 596, 664
activity 31, 48, 160, 427-429, 654
activity, enhancement of 592-593, 597, 611
activity, augmentation by interferon 591
cytotoxicity 339
and method of interferon application 642
neoplastic disease therapy, effect on interferon activity 360
neuraminidase 99
neuroendocrine system 354
neuroblastoma 643
neutral salts 673
neutralization
antibody 24, 45, 52
of endogenous interferon 165
interferon 23, 44
of interferon by heterologous antisera 352
neutrophiles
activation by interferon 151
and interferon treatment 651
Newcastle disease virus (NDV) 14, 64, 116-117, 125, 130, 137-138, 281, 359, 375
Nicotiana glutinosa 214-215,
non-antiviral
effects 219, 388
properties of mouse interferon 16

non-specific antiviral effects 140
non-viral infections 388
noradrenaline 346
northern blot analysis 475
nucleic acid, structure-activity relationship 79
nucleotide sequence. See also DNA
fibroblast human interferon 208
IFLrA 207
nude mice 89
null cells 85-86

oligoadenylates 443. See also 2'-5' oligoadenylate
oligonucleotides, presence in interferon-treated cells 481, 485
oncogenic viruses 582
oocyte(s) 24
orthomyxoviruses (influenza virus) 327
osteosarcoma 622, 650, 655
ouabain 309, 313, 371-372
oxyphenylbutazone 502-503

pactamycin 378
papilloma 623
papovavirus 546
paramyxovirus, heat and UV inactivated 65
passive transfer 366
pathogenic bacteria 151-152
Penicillium chrysogenum 144
periodate 241
persistent viruses 166
pertussis vaccine 363
PG19 (9) 14
phagocytes, mononuclear 420
phagocytosis 61, 391, 420
enhancement, basic mechanism of 378
modulation of 375ff
pharmacokinetic(s) 336
beta interferon 641
properties 544
pharyngoconjunctivitis 559
phorbol
ester(12-0-tetradecanoylphorbol-13-acetate) (TPA) 108ff
12-monomyristate 109
12, 13-dibutyrate 109
phosphodiesterase, activation of 603
phosphokinase 488
phospholipids 499ff
phosphorylation
double-stranded RNA dependent 463
eIF2 603
protein 493-494
phytohemagglutinin (PHA) 59, 90, 100, 109, 219, 310, 318, 519. See also: inducers; induction
picornavirus epidemic conjunctivitis 140, 538
plasma membrane. See membrane
plasmid constructions, for expression in E. coli 194
plasminogen activator 314
plateletpheresis 109
pleiotropic
effects of interferon 467, 499
effects of TPA 108
pokeweed mitogen 59, 110
poly(A)·poly(U) 79, 475
poly ICLC 130, 145, 527, 534, 658-662
polyIC·poly-L-lysine 123, 555
poly(I)·poly(C) 14, 76-77, 85, 111, 117-118, 121-124, 130, 144, 148, 171, 281, 359, 363, 376, 474, 489, 526-527, 533, 575, 591-592, 658,663. See also: inducers; induction
polyclonal sheep anti-interferon antibody 20
polyene antibodies 123-124
polynucleotide(s) 76-78, 130-131. See also nucleotide sequences
polypeptide(s)
hormones 38, 344
virus specific, synthesis of 606
polyribonucleotides 122. See also poly(I)·poly(C)
post-transcriptional modifications 463
potentiation 195, 327, 363, 539
anticellular 304
antitumor 305-306
antiviral 298, 303-304
clinical application 301
priming 14, 407
production of interferon 59, 84, 108, 122ff, 126, 179, 184, 192, 318, 364. See also: chromatography; purification
blocking 126
enhancement 15
gamma, cell types 260-261

production of interferon (continued)
large scale 169, 175, 672ff
microcarrier 169ff
natural 404
refractoriness 126
propane diamines 129-130
prophylactic treatment 557
prophylaxis, influenza 549
prophylaxis, of viral infections 545
prostaglandin(s) 7, 137, 439, 509, 576, 585, 685. See also inducers; induction
E 166
and hyporeactivity 132
modulation of induction by 117-118, 121
prostate cancer 628, 665
protein kinase 78, 324, 328, 412-413, 463, 471, 479
cAMP-dependent 494-495
cAMP independent 464
double-stranded RNA-dependent 494
interferon induced 493
membrane associated 496
purification 466
RNA activated 443, 664
protein synthesis 76
inhibition of 78-79, 443, 463, 487-489
protoplast system 213, 215
protozoa 388
protozoal infections, action of interferon 150ff
proximal inducer 64. See also γ induction
pseudogenes 193
psychopathological state 354
P388 tumor cells 300, 305-306
purification 24, 225, 234, 240-241, 250, 672ff. See also chromatography; production
affinity chromatography 15
chromatography, high pressure liquid 21
gamma interferon 436, 672
human alpha interferon 43, 47, 53, 225, 250
lymphokines 436
multi-stage process 176
of murine interferons 219
protein kinase 466
purified interferon, effect on phagocytosis 378
pyrimidines 129
pyrimidinones 117-118, 121, 159
pyrogenicity 146, 291, 293, 664

quantitative aspects of the interferon system 151

rabies 526ff
vaccine 141, 526
radioactive interferon 209
radioimmunoassay(s) 20, 46, 50, 56-59, 287, 480. See also assay
radioisotopes 209
radio labeling 209
reabsorption, renal 337
reactivation 276, 396
receptor(s) 324, 350-351, 403, 500, 686
activation of 308
glycoprotein 307, 310, 518
locus, interferon (IFRC) 324
membrane 99, 307, 309, 313-314, 336, 517
system 391
recombinant
DNA technology 192, 198. See also DNA
human leukocyte interferon, activity 48, 54
interferon(s) 31, 33, 46, 208
interferon IFL-γ3 45
interferon IFLrA 46-48, 200-202, 207
reference antisera 296
reference preparations 294
regulation of interferon system 317
remazol brilliant blue R 237-238
renal cell cancer 628
renal filtration 337-338
renaturation of interferon 275
reovirus 65
induction by 74
protein synthesis, inhibition of 465
replication, viral, inhibition of 540
replicative intermediate 474
repressor 95
respiratory infection(s) 549, 648
prevention of 563
resistance to interferon 303, 667
resistance to hydrolysis 130
retrovirus
replication 603-607
effect of interferon on 604
rheumatoid arthritis 165, 168

rhinovirus 549-550
RIA. See radioimmunoassay
ribonuclease 452
rickettsia 388
RNA
  double-stranded (dsRNA) 129, 144, 407-409, 443, 471, 479, 575ff
    complexes 144
    from natural sources 144
    induction by 64, 76
    mismatched 663
    mismatched analog 664
    $RI_n \cdot r(12,U)_n$ 663ff
    toxicity 663
    tumor therapy with 577-578
  messenger (mRNA) 66, 111, 125, 192, 198, 345, 452, 456
    degradation 465
    endonuclease cleavage of 474
  globin 382
  methylation of 476
  ribosomal, breakdown 481
  transfer (tRNA), deficiencies in interferon-treated cells 487
  viral 474, 487, 603
RNase, 2-5A-dependent 479-480

safety, clinical use 177
saliva, antiviral activity of 397
sarcoma, soft tissue 641
schizophrenia 140-141
scleroderma 165, 168
screening of transformants 206
SDS 15, 276, 370
secondary messenger molecules 344
Semliki Forest virus 65, 137, 522
Sendai virus 14, 176
senile dementia 141
sensitivity to interferon 325, 339
  viral 532-533, 550
sensitization 422
serum-free conditions 91
serum interferon
  in autoimmune disease 164
  in baboons 145-146
sialic acid 518
side effects 290, 338, 544, 562-563, 568, 573, 576-577, 585, 616-617, 622, 624, 636-637, 651, 659, 695
  double-stranded RNA therapy 146, 664, 666
silicic acid 673

Sindbis virus 65, 138-139
  induction by 73
  ts-mutants 65
Simian virus. See SV40 virus
site of action 150
6-mercatopurine 360
Sjogren's syndrome 165, 168
skin diseases 648
skin tumors, induced, UV 300
sodium butyrate 176
sodium dodecyl sulphate 15, 276, 370
sodium periodate (NaIO4) 100
solid phase antibody-binding assay (SABA) 43, 54
somatic cell
  genetics 94
  hybrids 307
  hybrid, mouse-human 324
species specificity 13, 26, 37, 280, 308, 325, 346
  immune interferon 185-186
specificity differences 39
spleen cells 347
splenectomy, effect of, on phagocytosis 376
spontaneous interferons 24
squamous cell carcinoma 636, 650
stability 15, 176, 544
  adsorption to surfaces 236
  in body fluids 359
  gamma interferon 276, 672
  guanidine hydrochloride 15
  heat 59, 275
  mechanical stress inactivation 276
  modified interferons 275
  pH2 59, 185, 222, 261, 276
  temperature 221
  temperature sensitive mutants 15
stabilization 274-275, 676, 680
standardization 294
staphylococcal enterotoxin A (SEA) 59, 100, 110, 179ff, 219, 317-318, 320, 389. See also inducers; induction
Staphylococcus epidermidis 152
sterility 293
steroid hormones 346
steroidogenesis 346
structure of interferon 250
subtypes. See also heterogeneity
  alpha interferon 23-26, 32, 44, 192-195, 252, 259, 543, 595

subtypes (continued)
beta interferon 95, 184-186, 288
sulphated polysaccharide, viral inhibitors 396
superinduction 14, 66, 95, 125, 171, 287. See also induction; production
superoxide dismutase 502-503, 506-507
suppressor lymphocytes 346-347, 611
surface typography probe 235
SV40 virus 603
replication, inhibition of 465
transformed cells 510
synergism antibody-interferon 539. See also potentiation
systemic lupus erythematosus 164-165, 168

target cell protection 599
T-cell(s) 85-86, 317, 325, 422, 504, 576
growth factors 90
mitogenic factor 436
mitogenic stimulation of 108
mitogens 100
temperature-sensitive (ts) mutants 64-65
10 carboxymethyl-9-acridanone (CMA) 158
teratocarcinoma cells 14
tetanus toxoid 59
tetraalkyl ammonium chlorides 236, 673
tetramethylammonium chloride 673, 677-678, 680
theophylline 364
therapy 540, 543, 550, 622-624, 639. See also side effects
administration of interferon, intralesional injection 657
dosage 300, 338, 655-658. See also dose
herpes simplex virus 533
induction 129
low dose 639
route of administration 561-563, 635, 648
tumor 664
3T3-L cells, insulin-stimulated 333
thymocyte stimulating factor. See interleukin 2
thymocytes 90
thyrotropin 350
tilorone 117-118, 121, 129, 159, 363, 376
T lymphocytes. See T-cells

tobacco mosaic virus (TMV) 139, 214-215
topical application 561-563, 648
toxicity 289-290, 338, 545, 560
of double-stranded RNA 663
hematologic 568
in newborn animals 408
toxin(s) 281, 308. See also specific toxins
toxoplasma 151, 390
transcription 95-96
transducers 351
transendothelial exchange 339
transfer, passive 366
transfer RNA. See RNA
transfer of viral resistance 345
transformed cells 175
translation, inhibition of 464
transmissible gastroenteritis virus 139
transplantation, allograft 421
triacylglycerol 500-501
trisomy 16, mouse 37
trisomy 21 37-38, 324, 326, 421
trp operator 201
trypanasomes 151
trypsin sensitive molecules, viral inhibitors 396
tumor(s)
animal, responding to interferon treatment 613
malignant, in children 641
models, animal 654
nectosis factor 60
P388 cells 300, 305-306
therapy, with leukocyte (alpha) interferon 622-624. See also therapy
tunicamycin 25, 221, 333
2-amino-5-bromo-6-methyl-4-primidinol 132
2'-dATP 475
2'-phosphodiesterase 472, 487-489
2'-5'A(pppA2'p5'A2'p5'A) 479
2'-5' oligadenylate synthetase 328, 443, 452-453, 455, 463-464, 488-491, 496, 499, 510, 664-665, 685
2'-5' oligodenylates 443, 444-445, 453, 471-472, 475, 479ff
Type I interferon 13, 23-27, 307. See also alpha/beta interferon
Type II interferon 13, 23-27. See also gamma interferon

U-amnion cells 372
urea 15
urine 337

vaccine, rabies 526
vaccinia virus 138, 299
Varicella-Zoster virus 532
vasculitis 164-165, 168
vesicular stomatitis virus (VSV) 137, 299, 315, 317, 320, 376, 550
  defective-interfering particles 65, 71
  induction by 73
  ts mutants 65
vinblastine 309
vincristine 309, 360
viral
  multiplication, enhancement 522
  inactivation, defective interfering particles 64-66, 71
  inactivation, ultra-violet light 64
  -induced interferon 64, 73, 85, 135ff, 150, 166, 219, 324. See also induction
  infection, enhancement by anti-interferon serum 522
  inhibitors, non-interferon, in cell culture 398
  inhibitors, serum, non-specific 395
  reinfections 540
  stability, heat 64
  translation, inhibition of 463
viremia 568
virions 604-605
virus. See also specific viruses
  assembly 606
  gastroenteritis 139
  implantation 540
  -induced interferon 298
  interferon-inducing particle (IFP), activity of 70
  inhibition 395
  neutralizing activity (VNA) 397
  persistent 166
  uptake, inhibition of 606
  variants, interferon induction by 136-139
V-3 cells, interferon assay on 145

warts, viral 648
West Nile virus 138
wheat germ agglutinin 110
WISH cells 347

Xenopus laevis 199
xenopus oocytes in translation systems 67